«Taken together, these two studies suggest that the new
scalable vaccine formulation is likely to prove as effective as the original formulation — which would make it the first protective TB vaccine in humans since BCG, which was introduced almost a century ago,» said Professor Ajit Lalvani, Director of the Tuberculosis Research Centre, National Heart and Lung Institute, Imperial College London and a member of the DAR - 901 development team.